A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Part of paid clinical trials in Sarasota, Florida.

Sponsor
Erasca, Inc.
Study ID
NCT06983743
Phase
PHASE1
Status
Recruiting

Conditions

  • Metastatic Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • ERAS-0015 — DRUG
    ERAS-0015 Administered orally
  • ERAS-0015 in combination — DRUG
    ERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.

Study Details

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.

Key Dates

Start date
Jun 5, 2025
Status verified
Sep 2025
Primary completion
May 1, 2028
Completion
Dec 1, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: ERAS-0015 Monotherapy Dose Optimization.
    Escalating doses of ERAS-0015 administered orally.
  • Experimental: ERAS-0015 Combination Dose Optimization
    ERAS-0015 administered orally with another investigational agent.

Primary Outcome Measure

Dose Limiting Toxicities (DLT) [ Time Frame: Study Day 1 up to Day 21 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Florida Cancer SpecalistsSarasotaFlorida34232-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030-
University of Texas at TylerTylerTexas75701-
NEXT VirginiaFairfaxVirginia22031-

Find similar trials in Sarasota, FL

Related Studies